Open AccessGemigliptin: Newer promising gliptin for type 2 diabetes mellitus
Author(s) -
Manish Gutch,
Abhay Joshi,
Sudhir Kumar,
Avinash Kumar Ágarwal,
Rajendra Kumar Pahan,
Syed Mohd Razi
Publication year - 2017
Publication title -
indian journal of endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.456
H-Index - 28
eISSN - 2230-9500
pISSN - 2230-8210
DOI - 10.4103/ijem.ijem_20_17
Subject(s) - medicine , metformin , type 2 diabetes mellitus , pharmacology , adverse effect , type 2 diabetes , dipeptidyl peptidase 4 , drug , diabetes mellitus , intensive care medicine , endocrinology
The dipeptidyl peptidase-4 (DPP-4) inhibitors have facilitated the management of type 2 diabetes mellitus (T2DM) owing to their superior efficacy and safety with low incidence of adverse effects. Gemigliptin is a new member of this family of drugs, and studies have revealed certain advantages of gemigliptin use compared to its previous congeners. Besides, this drug has also been studied for the treatment of T2DM as monotherapy, in combination with metformin or other oral antidiabetic drugs and in T2DM with moderate-to-severe renal failure. In this review, we explore the published data highlighting the pharmacology, efficacy, and safety of gemigliptin along with its recommendations for use in patients with T2DM.